Abstract 1434P
Background
The spatial architecture of B and T cells in the tumor microenvironment (TME) is known to be associated with treatment response in cancer patients. However, more complex spatial statistics to characterize the interaction of more than two immune cell types could further inform our understanding of tumor response to immunotherapy (IO). In this work we sought to evaluate quantitative metrics of higher order spatial relationships between multiple (>2) cell types to better characterize and predict overall survival (OS) in NSCLC patients.
Methods
The study included quantitative immunofluorescence images of pre-IO tumor biopsy specimen of 135 NSCLC patients from five centers with OS information. To predict OS, a set of 223 image features that characterize the spatial interplay of different cell types (CD4+, CD20+, CD8+, tumor, and stroma) in the TME were extracted. First, every nucleus belonging to each immune cell family was detected using an image analysis program (MATLAB) to identify the cell’s expression, subsequently the cell coordinates were recorded. The algorithm then identifies each triplet of distinct cells in proximity of each other to form spatial triangles. Features relating to the density, neighborhood, and proximity of nuclei were subsequently extracted. A risk score (RS) was then computed for each patient using the least absolute shrinkage and selection operator. To predict OS, the Cox regression model was trained on 100 patients (St) and validated on 35 patients (Sv). The discriminative ability of the features was assessed using Kaplan-Meier and log-rank tests.
Results
The RS was significantly associated with OS in both St (HR: 1.76; 95% CI = 1.09 - 2.85; P = .02), and Sv (HR: 2.8; 95% CI= 1.18–6.68; P=.01). RS based risk stratification showed greater accumulation of tumor, CD4 T cells, and CD20 B cells in very close proximity of each other in low-risk patients, compared to high-risk patients.
Conclusions
Machine learning derived features describing the higher order spatial relationships between tumor, CD20 B cells, and CD4 T cells were found to be associated with OS in NSCLC patients treated with IO. Additional, independent multi-site validation of these findings is warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
K. Schalper: Financial Interests, Speaker, Consultant, Advisor: Agenus, Ariagen, AstraZeneca, Bristol Myers Squibb , Clinica Alemana de Santiago, Genmab, Merck Sharp and Dohme, OnCusp Therapeutics, Repertoir Therapeutics, Takeda Oncology; Financial Interests, Institutional, Research Grant: Akoya Biosciences, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb , Eli Lilly and Company , Merck Sharp and Dohme, Navigate Biopharma, Pierre-Fabre, Ribon Therapeutics, Surface Oncology, Takeda Oncology, Tesaro, Inc.; Financial Interests, Advisory Board: EMD Serono, Shattuck Labs; Financial Interests, Research Grant: Moderna Inc. A. Madabhushi: Financial Interests, Personal, Advisory Board, Serve on SAB and consult: SimbioSys; Financial Interests, Personal, Advisory Board: Aiforia, Picture Health; Financial Interests, Personal, Full or part-time Employment: Picture Health; Financial Interests, Personal, Ownership Interest: Picture Health, Elucid Bioimaging, Inspirata Inc; Financial Interests, Personal, Royalties: Picture Health, Elucid Bioimaging; Financial Interests, Institutional, Funding: AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly. All other authors have declared no conflicts of interest.
Resources from the same session
1453P - Trends in treatment regimens and survival in the use of immune checkpoint inhibitors for lung cancer treatment in the Netherlands from 2016-2020
Presenter: Erick Suazo Zepeda
Session: Poster session 20
1454P - Radiomic analysis predicts response to immunotherapy in metastastic non-small cell lung cancer (mNSCLC): Preliminary results
Presenter: Salvatore Grisanti
Session: Poster session 20
1455P - Nivolumab (nivo) resumption in patients with advanced or metastatic non-small cell lung cancer (aNSCLC): Survival outcomes based on France and Germany real-world data (RWD)
Presenter: Maurice Pérol
Session: Poster session 20
1456P - Exploring biological and molecular factors as outcome predictors for pembrolizumab (Pem) or pembrolizumab-chemotherapy (Pem-CT) in advanced non-small cell lung cancer (NSCLC)
Presenter: Lodovica Zullo
Session: Poster session 20
1457P - Oligometastatic non-small cell lung cancer: Impact of local and systemic treatment approaches on clinical outcome
Presenter: Marcel Wiesweg
Session: Poster session 20
1459P - Preliminary efficacy and safety of KN046 (a bispecific anti-PD-L1/CTLA-4) in patients with metastatic non-small cell lung cancer who previously treated with immune checkpoint inhibitor(s)
Presenter: Caicun Zhou
Session: Poster session 20
1460P - GALLANT-1: GB1211 galectin-3 (Gal-3) inhibitor plus atezolizumab (atz) for first line treatment in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC)
Presenter: Francisco Aparisi Aparisi
Session: Poster session 20
1461P - Predictive value of residual FDG-PET metabolic activity in metastatic non-small cell lung cancer (mNSCLC) patients (pts) with long-lasting response to immune checkpoint inhibitors (ICIs)
Presenter: Toublanc Anne-Claire
Session: Poster session 20
1463P - IL-6 triggers chemoimmunotherapy resistance by creating immunosuppressive tumor microenvironment in non-small cell lung cancer
Presenter: Yaning Yang
Session: Poster session 20